BioCentury
ARTICLE | Company News

R-Tech Ueno, Sucampo deal

March 16, 2015 7:00 AM UTC

Sucampo returned all rights to unoprostone isopropyl ( UF-021) to R-Tech after the product missed the primary endpoint in a Japanese Phase III trial to treat retinitis pigmentosa (RP). Last year, Suca...